Advertisement

Acquired Coagulation Inhibitors in the Non-Congenital Factor Deficient Population: Clinical Manifestations and Management

  • A. Moliterno
  • W. R. Bell
Conference paper

Abstract

Although antibodies to coagulation proteins occur frequently in the patients with congenital deficiencies of procoagulant proteins, their appearance in the non-hemophilic population is rare [1] Offsetting the rarity of these inhibitors is the severity of the clinical consequences of what has been termed acquired hemophilia; when these inhibitors do appear, they produce recurrent, devastating hemorrhage.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ehrenforth S, Kreuz W, Scharrer I et al. (1992) Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339: 594–598PubMedCrossRefGoogle Scholar
  2. 2.
    Green D, Lechner K (1981) A survey of 215 non-hemophilic patients with inhibitors to FVIII. Thromb Haemost 45: 200–203PubMedGoogle Scholar
  3. 3.
    Lottenberg R, Kentro TB, Kitchens CS (1987) Acquired haemophilia: a natural history study of the patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 147: 1077–1081PubMedCrossRefGoogle Scholar
  4. 4.
    Biggs R (1976) Human blood coagulation, haemostasis and thrombosis. Bladenwell, Oxford, pp 702–704Google Scholar
  5. 5.
    Kasper C (1975) A more uniform measurement of factor VIII inhibitor. Thromb Diath Haemorrh 34: 869–872Google Scholar
  6. 6.
    Spero JA, Lewis JH, Hasiba U (1981) Corticosteroid therapy for acquired Factor VIII:C inhibitors. Br J Haematol 48: 635–642PubMedCrossRefGoogle Scholar
  7. 7.
    Algiman M, Dietrich G, Nydegger U et al (1992) Natural antibodies to Factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci USA 89: 3795–3799PubMedCrossRefGoogle Scholar
  8. 8.
    Green D, Rademaker AW, Briet E (1993) A prospective randomized trial of prednisone and cyclophosphamide in the treatment of patients with Factor VIII autoantibodies. Thromb Haemost 70: 753–757PubMedGoogle Scholar
  9. 9.
    Lian EC-Y, Larcada AF, Chiu AY-Z (1989) Combination immunosuppressive therapy after Factor VIII infusion for acquired Factor VIII inhibitor. Ann Intern Med 110: 774–778PubMedGoogle Scholar
  10. 10.
    Gilles JG, Saint-Remy JR (1994) Healthy subjects produce both anti-Factor VIII and specific anti-idiotypic antibodies. J Clin Invest 94: 1496–1505PubMedCrossRefGoogle Scholar
  11. 11.
    Ludlam CA, Morrison AE, Kessler C (1994) Treatment of acquired hemophilia. Semin Hematol(Suppl) 31: 16–19Google Scholar
  12. 12.
    Allain JP, Gaillandre A, Frommel D (1981) Acquired hemophilia: Functional study of antibodies to Factor VIII. Thromb Haemost 45: 285–289Google Scholar
  13. 13.
    Arai M, Scandella D, Hoyer LW (1989) Molecular basis of Factor VIII inhibition of human antibodies. J Clin Invest 83: 1978–1984PubMedCrossRefGoogle Scholar
  14. 14.
    Hoyer LW, Gawryl MS, de la Fuente B (1984) Immunochemical characterization of Factor VIII inhibitors. In: Hoyer Lw (ed) Factor VIII inhibitors. Liss, New York, pp 73–85Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • A. Moliterno
  • W. R. Bell

There are no affiliations available

Personalised recommendations